Retroperitoneal Sarcoma: Fact, Opinion, and Controversy

Rebecca A Gladdy; Abha Gupta; Charles N Catton

doi:10.1016/j.soc.2016.05.003

Retroperitoneal Sarcoma: Fact, Opinion, and Controversy

Surg Oncol Clin N Am. 2016 Oct;25(4):697-711. doi: 10.1016/j.soc.2016.05.003. Epub 2016 Jul 30.

Authors

Rebecca A Gladdy¹, Abha Gupta², Charles N Catton³

Affiliations

¹ Department of Surgery, Mount Sinai Hospital, University of Toronto, 600 University Avenue, Suite 1225, Toronto, Ontario M5G 1X5, Canada; Department of Surgical Oncology, Princess Margaret Cancer Centre, 610 University Avenue, 3rd Floor, Toronto, Ontario M5G 2M9, Canada. Electronic address: rgladdy@mtsinai.on.ca.
² Division of Pediatric Hematology/Oncology, Department of Pediatrics, The Hospital for Sick Children, University of Toronto, Room 9215, Toronto, Ontario M5G 1X8, Canada; Department of Medical Oncology, Princess Margaret Cancer Centre, 610 University Avenue, 5th Floor, Toronto, Ontario M5G 2M9, Canada.
³ Department of Radiation Oncology, University of Toronto, FitzGerald Building, Room 106, 150 College Street, Toronto, Ontario M5S 3E2, Canada; Radiation Medicine Program, Princess Margaret Cancer Centre, 610 University Avenue, 5th Floor, Toronto, Ontario M5G 2M9, Canada.

PMID: 27591493
DOI: 10.1016/j.soc.2016.05.003

Abstract

After diagnosis of retroperitoneal sarcoma (RPS), detailed imaging and multidisciplinary discussion should guide treatment including surgical resection and in select cases, neoadjuvant therapy. Local recurrence is common in RPS and is associated with grade, histologic subtype, completeness of resection, and size. As guidelines to standardize RPS patient management emerge, expert pathologic assessment and management in centers of excellence are benchmarks of quality of care. The efficacy of current chemotherapy is limited and there is a critical need to understand the molecular basis of sarcoma so that new drug therapies are developed. Multicenter clinical trials are needed to limit opinion and controversy in this complex and challenging disease.

Keywords: Chemotherapy; Local recurrence; Radiation therapy; Retroperitoneal sarcoma; Soft tissue sarcoma; Surgery.

Publication types

Review

MeSH terms

Combined Modality Therapy / methods*
Combined Modality Therapy / trends
Humans
Neoadjuvant Therapy
Neoplasm Recurrence, Local
Retroperitoneal Neoplasms / pathology*
Retroperitoneal Neoplasms / surgery*
Sarcoma / pathology
Sarcoma / surgery*
Sarcoma / therapy
Treatment Outcome